Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
ElsMed
Ampronix

Early PET-Negative Stage I/II Hodgkin Lymphoma Patients Show Increased Risk of Early Relapse when Radiotherapy Is Not Used

By Medimaging International staff writers
Posted on 23 Apr 2014
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).
Analysis of a new study indicates an increased risk of early relapse when excluding radiotherapy in early positron emission tomography (PET) scan-negative patients with stage I/II Hodgkin’s lymphoma.

The interim analysis of the intergroup EORTC-LYSA-FIL 20051 H10 trial was published online March 17, 2014, in the Journal of Clinical Oncology. Early outcome, however, was excellent in both arms, and the final analysis should reveal whether these preliminary findings are upheld over time.

Dr. J.M.M. Raemaekers, from the Radboud University Medical Center (Nijmegen, The Netherlands), and central coordinator of the study stated, “The standard treatment for patients with clinical stage I/II Hodgkin’s lymphoma is ABVD [adriamycin, bleomycin, vinblastin and dacarbazin] chemotherapy followed by radiotherapy. Striking the right balance between initial cure through combined modality treatment and accepting a higher risk of late complications, and a higher recurrence rate after omitting radiotherapy in subsets of patients who will subsequently need intensive salvage treatment, is a matter of unsettled debate.”

The main objective of the H10 trial was to evaluate whether involved-node radiotherapy could be omitted without loss of efficacy in terms of progression-free survival in patients with stage I/II Hodgkin’s lymphoma who had a negative early PET scan after two cycles of ABVD chemotherapy. This interim trial analysis included a total of 1,137 patients with untreated clinical stage I/II Hodgkin’s lymphoma. Of these, 444 patients had favorable and 693 unfavorable prognoses. Patients in each prognostic group were randomized between standard and experimental treatment and first received two cycles of ABVD chemotherapy. Patients in the experimental arm who attained a negative early PET scan after the two cycles of ABVD chemotherapy were spared involved-node radiotherapy.

One progression occurred in the standard arm and nine progressions occurred in the research arm, for patients with a favorable prognosis and a negative early PET scan. For patients with unfavorable prognosis and a negative early PET scan, seven events occurred in the standard arm and 16 events occurred in the research arm. Even though there were few events and the median follow-up time short, the Independent Data Monitoring Committee concluded it was unlikely that the final results would show noninferiority for the experimental treatment. They, therefore, advised that randomization should be stopped for early PET-negative patients.
The study was closed for recruitment in June 2011 with a total of 1952 patients. The intergroup EORTC 20051 H10 trial is coordinated by the EORTC Lymphoma Group in collaboration with the LYmphoma Study Association (LYSA) and the Fondazione Italiana Linfomi (FIL). It is being conducted in 159 sites in eight countries: Belgium, Croatia, Denmark, France, Italy, Slovakia, Switzerland, and The Netherlands.

Related Links:

Radboud University Medical Center



Channels

Radiography

view channel
Image: The Somatom Scope CT system’s biopsy and intervention modes for CT-guided intervention enhance precision and streamline workflow (Photo courtesy of Siemens Healthcare).

16-Slice CT System’s Technology Extends Operational Lifetime by Minimizing Wear and Tear

A new 16-slice computed tomography (CT) system is designed for clinical routine and is available in two power configurations to better meet clinical, workflow requirements. Siemens Healthcare (Erlangen,... Read more

MRI

view channel

fMRI and Circuitry Mapping Shows Dyslexic Readers Have Disrupted Brain Network

Dyslexia, the most typically diagnosed learning disability in the United States, is a neurologic reading disability that occurs when the regions of the brain that process written language do not function normally. The use of noninvasive functional neuroimaging approaches has helped characterize how brain activity is disrupted... Read more

Ultrasound

view channel
Image: Leading German anesthetists Drs. Wolf Armbruster, Rüdiger Eichholz, and Thomas Notheisen have collaborated to develop the Armbruster Eichholz Notheisen (AEN) training concept for ultrasound-guided regional anesthesia (Photo courtesy of Management and Krankenhaus).

Point-of-Care Ultrasound Training Program Established for Regional Anesthesiologists

Regional anesthesia specialists have developed an innovative ultrasound training program. Leading German anesthetists Drs. Wolf Armbruster, Rüdiger Eichholz, and Thomas Notheisen have collaborated to... Read more

General/Advanced Imaging

view channel
Image: New laser technology designed to detect breast cancer based on photoacoustics (Photo courtesy of Universidad Carlos III de Madrid).

Photoacoustics Used to Detect Breast Cancer

Spanish scientists are using new laser technology to detect breast cancer based on photoacoustics. The new approach could become an alternative to mammography or ultrasound. The European science project... Read more

Imaging IT

view channel

Database Tool Centralizes Imaging Workflows into One Platform to Improve Patient Care, Cut Costs

A single database application has been developed to centralize imaging workflows into one easy-to-use platform. It is an intuitive approach that scales as the healthcare provider’s needs grow. With consolidated software and interfaces, users can considerable reduce manual data entry, errors, and down time.... Read more

Industry News

view channel

Global Partnership Provides Treatment Planning Support for Modulated Arc Radiotherapy

Varian Medical Systems (Palo Alto, CA, USA) Eclipse treatment planning software can now be used to plan modulated arc radiotherapy (mARC) treatments at sites using Siemens Healthcare (Erlangen, Germany) medical linear accelerators. Varian Medical Systems and Siemens Healthcare presented their range of solutions that... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.